Nanosuspension: An Emerging Trend for Bioavailability Enhancement of Etodolac

Table 1

Drug content, percentage yield, particle Size (P.S.), and size distribution of nanosuspensions prepared by pH shift method.

Formula code	Stabilizer	Drug content (%); pH shift method	% Yield; pH shift method	P.S. in nm	PdI^*
F1	Crude drug	—	—	3676 ± 42.6	0.52
F2	Nanosuspension without stabilizer	100	99.46	7129 ± 63.2	1.00
F3	Na CMC	98.7	92.02	827 ± 5.4	0.49
F4	HPMC	89.5	90.91	1025 ± 11.14	0.56
F5	PVP K44	85.3	93.75	1702 ± 97.2	0.72
F6	PVA	90.0	96.77	2000 ± 50.7	0.85
F7	PEG 400	92.6	95.54	790 ± 3.3	0.51
F8	Tween 20	95.7	90.91	618 ± 4.5	0.49
F9	Tween 80	92.5	90.36	393 ± 2.05	0.34
F10	β-cyclodextrin	98.2	96.77	866 ± 5.9	0.53

PdI^*: polydispersibility index.